DocDollars

Adamas Pharmaceuticals, Inc.

MD · United States · Reporting entity ID 100000226811

Total reported 2019–2025
$11.5M
#452 of 2,960 reporting companies — 0% of all reported industry payments
$2.36M in general payments across 20,061 records, plus $9.16M in research funding across 3,041 records.

How it breaks down

General payments $2,362,915
Research funding $9,163,263

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Adamas Pharmaceuticals, Inc. reported $11.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #452 of 2,960 reporting companies. 79% of that was research funding and 21% general payments such as consulting, speaking, food and travel. 20,061 general payment records and 3,041 research records were filed.

Common questions about Adamas Pharmaceuticals, Inc.

How much has Adamas Pharmaceuticals, Inc. paid US doctors?

Adamas Pharmaceuticals, Inc. reported $11,526,179 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $2,362,915 in general payments, $9,163,263 in research funding.

How does Adamas Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #452 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Adamas Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.